Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | ADK | P55263 | 1/20 | 0.30 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL953387 | 0.91 | USP2 (0.33) | TAAR1F2RL1PTGDR2 | |
| SCHEMBL955179 | 0.87 | TAAR1 (0.34) | TAAR1F2RL1ADRA2AADRA2BADRA2C | |
| SCHEMBL953663 | 0.85 | MPO (0.34) | TAAR1F2RL1ADRA2AADRA2BADRA2C | |
| SCHEMBL957319 | 0.75 | TAAR1 (0.35) | TAAR1F2RL1ADRA2AADRA2BADRA2C | |
| SCHEMBL2104102 | 0.70 | PTGDR2 (0.30) | PTGDR2 | |
| SCHEMBL12011595 | 0.68 | NISCH (0.49) | TAAR1ADRA2AADRA2BADRA2CMTOR | |
| SCHEMBL6934133 | 0.67 | TAAR1 (0.47) | TAAR1ADRA2AADRA2BADRA2CMTOR | |
| SCHEMBL14909320 | 0.67 | TAAR1 (0.47) | TAAR1ADRA2AADRA2BADRA2CMTOR | |
| SCHEMBL8904389 | 0.67 | TAAR1 (0.47) | TAAR1ADRA2AADRA2BADRA2CMTOR | |
| SCHEMBL953334 | 0.66 | CHRM2 (0.43) | TAAR1F2RL1ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | TAAR1 117/4885F2RL1 1989/4885PTGDR2 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.